Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells 8,643 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 8,643 shares of ANI Pharmaceuticals stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the transaction, the director owned 61,405 shares in the company, valued at approximately $5,334,866.40. This represents a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded down $2.05 during mid-day trading on Monday, hitting $81.97. 853,525 shares of the company’s stock were exchanged, compared to its average volume of 373,460. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $99.50. The business’s 50 day moving average is $92.77 and its two-hundred day moving average is $78.24. The firm has a market capitalization of $1.84 billion, a P/E ratio of -106.45 and a beta of 0.54.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. During the same period in the prior year, the business earned $1.34 EPS. The firm’s revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Invesco Ltd. increased its stake in shares of ANI Pharmaceuticals by 1.0% during the 1st quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock worth $13,361,000 after purchasing an additional 2,022 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock valued at $15,959,000 after buying an additional 2,220 shares during the last quarter. State of Alaska Department of Revenue increased its position in ANI Pharmaceuticals by 10.0% during the second quarter. State of Alaska Department of Revenue now owns 10,116 shares of the specialty pharmaceutical company’s stock worth $659,000 after buying an additional 920 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of ANI Pharmaceuticals by 22.4% in the first quarter. Victory Capital Management Inc. now owns 16,863 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after acquiring an additional 3,086 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in shares of ANI Pharmaceuticals in the first quarter worth $11,144,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ANIP has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research note on Monday, November 10th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. HC Wainwright increased their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Finally, Guggenheim lifted their price objective on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a report on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $99.29.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.